Thermo Fisher Scientific Inc. (TMO) fair value analysis

S&P 500 · Updated 2026-09-07

Thermo Fisher Scientific Inc. is a global life sciences company that provides laboratory equipment, reagents, consumables, and services to customers in research, clinical diagnostics, and bioproduction. The company operates across multiple continents and serves customers in pharmaceutical, biotechnology, academic, and healthcare organizations worldwide.

Forward Fair Value verdict

Fairly valued

Based on TickrTrends' weekly Forward Fair Value model, TMO is trading at within about 10% of estimated fair value.

TMO currently ranks #65 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Fairly valued for 3 consecutive weekly runs.

Last price: $613.78
Sector: Healthcare
12-month range: $469.21–$600.50

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: C
Leverage: Moderate
Margin trend: Stable
Revenue growth: Modest
RSI zone: Neutral
52-week position: The top quarter of its range
DCF cross-check: Overvalued

What our data shows for TMO

Our model validated 17 trailing price-to-earnings windows for TMO, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $469.21–$600.50.
The 14-day relative strength index sits at a neutral 59.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for TMO
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent TMO news

TickrTrends' derived news-sentiment signal for TMO is currently leaning positive, computed from recent coverage.

HCLTech opens new Bengaluru semiconductor lab with ₹185-crore investment (telecom.economictimes.indiatimes.com, 2026-09-08)
TMO Initiated Coverage by CLSA -- Outperform Rating with Price Target of $748 (gurufocus.com, 2026-09-03)
TickrTrends take: CLSA's initiation of coverage with an Outperform rating and a price target of $748 provides a new analyst perspective on TMO, a Healthcare sector company currently assessed as Fairly valued by TickrTrends. For valuation-focused investors, the gap between CLSA's price target and the current market price will be an important metric to monitor, as it may indicate whether the market is repricing the company or whether analyst expectations diverge from broader valuation consensus. The timing and conviction of this coverage initiation could influence how the Fairly valued assessment evolves if the market begins to reflect CLSA's more positive outlook.
TMO DCF Analysis: Intrinsic Value $491 vs Price $622 (gurufocus.com, 2026-08-31)
TickrTrends take: TMO is currently trading at $622 while a discounted cash flow analysis suggests an intrinsic value of $491, indicating the stock is priced above this DCF-derived estimate. This valuation gap aligns with TickrTrends' assessment that TMO is fairly valued, suggesting the market is pricing in expectations beyond the baseline cash flow projections. Investors focused on valuation metrics should monitor whether TMO's operational performance and growth trajectory can justify the premium at which it currently trades in the Healthcare sector.

What people are saying

Follow the TMO conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' derived indicators for TMO show a notable shift this week, with the momentum indicator declining from A to none. Despite this change in momentum status, TMO remains classified as fairly valued within the Healthcare sector.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is TMO stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), TMO is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.

What is TMO's TickrTrends verdict?

TMO's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.

How does TMO compare to other Healthcare stocks?

TMO ranks #65 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is TMO overbought or oversold?

TMO's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

TMO vs BAX · TMO vs DHR · TMO vs HSIC · TMO vs INVA · TMO vs IQV